Trials / Completed
CompletedNCT00256685
Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
A Double-Blind, Randomized, Placebo-Controlled Efficacy and Safety Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 568 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Female
- Age
- 0 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with menopause, and also to assess the effects of DVS on sleep parameters and health outcomes indicators.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DVS-233 SR |
Timeline
- Start date
- 2004-09-01
- Completion
- 2005-07-01
- First posted
- 2005-11-21
- Last updated
- 2006-05-19
Source: ClinicalTrials.gov record NCT00256685. Inclusion in this directory is not an endorsement.